Morphic (MORF) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 -Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Of icer- "Morphic continues to execute our strategy with the EMERALD-2 phase 2b study in ulcerative colitis (UC) recruiting on target, and we are excited to begin enrollment in the GARNET phase 2 study in patients with moderate to severe Crohn's disease (CD)," commented ...